| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000015352 |
| Receipt No. | R000017848 |
| Official scientific title of the study | A randamized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of oral administration of probiotic LKM512 and arginine on function of vascular endothelium in individuals with pre-metabolic syndrome |
| Date of disclosure of the study information | 2014/10/07 |
| Last modified on | 2018/06/29 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | A randamized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of oral administration of probiotic LKM512 and arginine on function of vascular endothelium in individuals with pre-metabolic syndrome | |
| Title of the study (Brief title) | Effects of probiotic LKM512 and arginine on function of vascular endothelium | |
| Region |
|
|
| Condition | ||
| Condition | pre-metabolic syndrome | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy of oral administration of probiotic LKM512 and arginine on function of vascular endothelium in patients with pre-metabolic syndrome |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | RH-PAT(Endo-PAT) |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | The volunteer were given an 8-week treatment with oral administration of bifidobacteria LKM512 powder (6 billion bacterial cells/stick) and 3 arginine tablets (100mg/tablet) two times per day. | |
| Interventions/Control_2 | The volunteer were given an 8-week treatment with oral administration of placebo powder without bifidobacteria LKM512 and 3 placebo tablets without arginine two times per day. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Outpatients whose BMl is more than 25.0 | |||
| Key exclusion criteria | 1. Outpatients whose BMl is more than 25.0
2. Subjects who take a medicine for dyslipidemia treatment 3. Serious subjects who have complications with cardiac disease, hepatic disease,and/or renal disease 4. Subjects who had serious gastrointestinal disease in the past 5. Subjects who take hypotensive medicines 6. Subjects who have serious constipation 7. Subjects who was enrolled in other trails within one month 8. Inappropriate cases evaluated by doctors |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Mitsuharu Matsumoto |
| Organization | Kyodo Milk Industry Co. Ltd. |
| Division name | Research Laboratories |
| Address | 20-1 Hirai, Hinode-machi, Nishitama-gun, Tokyo 190-0182 |
| TEL | 042-597-5911 |
| m-matumoto@meito.co.jp | |
| Public contact | |
| Name of contact person | Satoshi Sakurai |
| Organization | imeQ CO. Ltd. |
| Division name | CRO division |
| Address | a vous primus Bld, 2-14-6, nishiwaseda, Shinjuku-ku, Tokyo 169-0075 |
| TEL | 03-6279-3591 |
| Homepage URL | |
| s-sakurai@imeq.co.jp | |
| Sponsor | |
| Institute | Kyodo Milk Industry Co. Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kyodo Milk Industry Co. Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団 札幌百合の会病院 (北海道) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017848 |